Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance ...